31.07.2015 Views

Advances in the stereoselective synthesis of antifungal agents and ...

Advances in the stereoselective synthesis of antifungal agents and ...

Advances in the stereoselective synthesis of antifungal agents and ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Chapter 4 103(+)-(S)-2-octylimidazole (+)-(S)-35a was chosen as target compoundfor <strong>the</strong> alternative syn<strong>the</strong>tic pathway <strong>and</strong> (+)-(S)-2-octyl am<strong>in</strong>e (+)-(S)-44(not commercially available) as start<strong>in</strong>g material.The syn<strong>the</strong>sis <strong>of</strong> (+)-(S)-2-octyl am<strong>in</strong>e (+)-(S)-44 is shown <strong>in</strong> scheme4.7. For this <strong>the</strong> commercially available (-)-(R)-2-octanol (-)-(R)-11c wasconverted by Mitsunobu reaction <strong>in</strong>to <strong>the</strong> (-)-(S)-2-octyl phtalimmidederivative (-)-(S)-45 which by treatment with hydraz<strong>in</strong>e was converted <strong>in</strong>to<strong>the</strong> desired (+)-(S)-2-octylam<strong>in</strong>e (+)-(S)-44. Us<strong>in</strong>g (+)-(S)-44 <strong>the</strong> firstsyn<strong>the</strong>sis was performed with racemic (±)-31c <strong>in</strong> order to check <strong>the</strong>strategy <strong>and</strong> also to obta<strong>in</strong> reference compounds.OOHPhtalamideDEAD, PPH 3dry THFNONH 2 NH 2RefluxNH 2(-)-( R)-31c (-)-( S)-45 (+)-( S)-44Scheme 4.7: Syn<strong>the</strong>sis <strong>of</strong> (+)-(S)-44.The thus produced (+)-(S)-44 had identical physical constants <strong>in</strong>comparison with <strong>the</strong> data reported <strong>in</strong> <strong>the</strong> literature 1 .Racemic 2-octylam<strong>in</strong>e (±)-44 treated with am<strong>in</strong>omalonitrile <strong>and</strong> triethylorth<strong>of</strong>ormiate <strong>in</strong> acetonitrile was lead<strong>in</strong>g <strong>the</strong> N-1-(2-octyl)-4-cyano-5-am<strong>in</strong>oimidazole (±)-46 5 <strong>in</strong> good yield. Us<strong>in</strong>g <strong>the</strong> same procedure identicalresults were obta<strong>in</strong>ed with enantiopure (+)-(S)-2-octyl am<strong>in</strong>e (+)-(S)-44lead<strong>in</strong>g to (+)-(S)-N-1-(2-octyl)-4-cyano-5-am<strong>in</strong>oimidazole (+)-(S)-46 <strong>in</strong>enantiopure form <strong>in</strong> 52% yield <strong>and</strong> 98% e.e (scheme 4.8).The alkal<strong>in</strong>e hydrolysis <strong>of</strong> <strong>the</strong> 5-am<strong>in</strong>o-4-cyano-N-1-imidazolederivatives (±)-46 <strong>and</strong> (+)-(S)-46 led to <strong>the</strong> am<strong>in</strong>o acids (±)-47 <strong>and</strong> (-)-(S)-47, respectively. The hydrolysis conditions were identical to those used for<strong>the</strong> hydrolysis <strong>of</strong> <strong>the</strong> dicyanoimidazole derivative (±)-33a <strong>and</strong> (-)-(R)-33a,<strong>and</strong> no racemization did occur dur<strong>in</strong>g this step. Compounds (±)-47 <strong>and</strong> (-)-(S)-47 were decarboxylated to <strong>the</strong> N-1-(2-octyl)-5-am<strong>in</strong>o imidazole (±)-48<strong>and</strong> (+)-(S)-48. Also <strong>in</strong> this case <strong>the</strong>rmal decarboxylation was used s<strong>in</strong>cedur<strong>in</strong>g this step on <strong>the</strong> compounds (±)-34a <strong>and</strong> (+)-(S)-34a noracemization occurred.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!